🔗 Permalink

Inventor profile of:

Daniel LADANT

City:

Cachan

Country:

France

Published Applications:

Last publication date:

2018-07-26

Top Assignees for applications by Daniel LADANT

The entities that hold a legal rights for patent applications filed by inventor LADANT Daniel:

Institut Pasteur 9 Paris, France
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE 7 PARIS, France
Genticel 3 Labege-Innopole, France
Institut National de la Sante et de la Recherche Medicale 3 Paris, France
Centre National de la Recherche Scientique 1 Paris, France
Institut Pasteur, a corporation of France 1 Paris, France
Ludwig Institute for Cancer, a corporation of New York 1 New York, NY United States
LUDWIG INSTITUT FOR CANCER RESEARCH 1 New York, NY United States
Daniel Ladant 1 Cachan, France
Institut National De La Sante Et De La Recherche Medicale (INSERM) 1 Paris, France
INSTITUT PASTEUR 1 PARIS CEDEX 15, France
Ludwig Institute for Cancer 1 New York, NY United States

Recent patent applications by LADANT Daniel

Daniel LADANT from Cachan, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2018-07-26

US20180208919A1

Chemistry; metallurgy

Monomeric and functional adenylate cyclase CyaA toxin

#2 | 2017-07-20

US20170204402A1

Chemistry; metallurgy

In vivo detection of proteins interaction based on adenylate cyclase hybrid system

#3 | 2016-12-29

US20160375119A1

Human necessities

Vectors for molecule delivery to CD11b expressing cells

#4 | 2014-08-14

US20140227323A1

Human necessities

RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS

#5 | 2014-08-14

US20140227308A1

Human necessities

Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof

#6 | 2012-08-23

US20120214206A1

Human necessities

Vectors for molecule delivery to CD11b expressing cells

#7 | 2011-07-14

US20110171244A1

Human necessities

Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof

#8 | 2011-03-17

US20110065782A1

Physics

METHODS OF IDENTIFYING COMPOUNDS THAT INHIBIT THE ACTIVATION OF A BIOMOLECULE AND METHODS OF TREATMENT USING THE COMPOUNDS

#9 | 2011-03-15

US11713708

Modified adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof

#10 | 2010-12-09

US20100310594A1

Chemistry; metallurgy

RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS

#11 | 2009-05-07

US20090117143A1

Chemistry; metallurgy

Recombinant adenylate cyclase toxin of induces T cell responses against tumoral antigens

#12 | 2007-03-29

US20070072266A1

Human necessities

Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof

#13 | 2007-02-01

US20070026022A1

Human necessities

Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens

#14 | 2006-07-20

US20060159697A1

Chemistry; metallurgy

Modified bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof

#15 | 2005-12-08

US20050271679A1

Chemistry; metallurgy

Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens

#16 | 2005-10-27

US20050238637A1

Human necessities

Vectors for molecule delivery to CD11b expressing cells

InventorID:

870952 ⎘